Cardiovascular risk factors in chronic kidney disease

Kidney International

Volumn 68, Issue 4, 2005, Pages 1413-1418

  Menon, Vandana ^a   Gul, Ambreen ^a   Sarnak, Mark J ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTERIOSCLEROSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; ELECTROLYTE DISTURBANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MICROALBUMINURIA; MYOCARDIAL DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 31644438457     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00551.x     Document Type: Conference Paper

References (46)

1. FOLEY RN, PARFREY PS, SARNAK MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16-S23, 1998
2. MANJUNATH G, TIGHIOUART H, IBRAHIM H, et al: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41:47-55, 2003
3. SARNAK MJ, LEVEY AS, SCHOOLWERTH AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
4. GO AS, CHERTOW GM, FAN D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305, 2004
5. WACHTELL K, IBSEN H, OLSEN MH, et al: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med 139:901-906, 2003
6. MANN JF, GERSTEIN HC, YI QL, et al: Development of renal disease in people at high cardiovascular risk: Results of the HOPE randomized study. J Am Soc Nephrol 14:641-647, 2003
7. MENON V, SARNAK MJ: The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: A high risk combination. Am J Kidney Dis 45:223-232, 2005
8. ZOCCALI C, BENEDETTO FA, MALLAMACI F, et al: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12:2768-2774, 2001
9. KLASSEN PS, LOWRIE EG, REDDAN DN, et al: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548-1555, 2002
10. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 20:32-38, 1992
11. LONDON GM, PARFREY PS: Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 4:194-211, 1997
12. MCMAHON LP, ROGER SD, LEVIN A: Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 15:1640-1647, 2004
13. MCALISTER FA, EZEKOWITZ J, TONELLI M, et al: Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 109:1004-1009, 2004
14. LONDON GM, MARCHAIS SJ, GUERIN AP, et al: Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 17:1713-1724, 2002
15. MOURAD JJ, PANNIER B, BLACHER J, et al: Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 59:1834-1841, 2001
16. WILSON PW, D'AGOSTINO RB, LEVY D, et al: Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847, 1998
17. LEVIN A, THOMPSON CR, ETHIER J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
18. STACK AG, SARAN R: Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 40:1202-1210, 2002
19. LEVIN A, SINGER J, THOMPSON CR, et al: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
20. ASTOR BC, ARNETT DK, BROWN A, et al: Association of kidney function and hemoglobin with left ventricular morphology among African Americans: The Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 43:836-845, 2004
21. YILDIZ A, MEMISOGLU E, OflAZ H, et al: Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant 20:760-767, 2005
22. ZOCCALI C, MALLAMACI F, ASAHIA K, et al: Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J Nephrol 14:293-298, 2001
23. CULLETON BF, LARSON MG, WILSON PW, et al: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
24. MUNTNER P, HE J, ASTOR BC, et al: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 16:529-538, 2005
25. LONGENECKER JC, CORESH J, POWE NR, et al: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 13:1918-1927, 2002
26. SARNAK MJ, CORONADO BE, GREENE T, et al: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57:327-335, 2002
27. MENON V, GREENE T, WANG X, et al: C-reactive protein and serum albumin as predictors of all-cause and cardiovascular mortality in patients with chronic kidney disease. Kidney Int 68:766-772, 2005
28. KNIGHT EL, RIMM EB, PAI JK, et al: Kidney dysfunction, inflammation, and coronary events: A prospective study. J Am Soc Nephrol 15:1897-1903, 2004
29. STENVINKEL P, KETTELER M, JOHNSON RJ, et al: IL-10, IL-6, and TNF alpha: Central factors in the altered cytokine network of uremia. The good, the bad, and the ugly. Kidney Int 67:1216-1233, 2005
30. HIMMELFARB J, STENVINKEL P, IKIZLER TA, et al: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
31. MANN JF, LONN EM, YI Q, et al: Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 65:1375-1380, 2004
32. BOAZ M, SMETANA S, WEINSTEIN T, et al: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356:1213-1218, 2000
33. TEPEL M, VAN DER GIET M, STATZ M, et al: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 107:992-995, 2003
34. PALANIAPPAN L, CARNETHON M, FORTMANN SP: Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 16:952-958, 2003
35. FORD ES: The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:307-312, 2004
36. SHINOHARA K, SHOJI T, EMOTO M, et al: Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13:1894-1900, 2002
37. ZOCCALI C, MALLAMACI F, TRIPEPI G, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141, 2002
38. BOUSHEY CJ, BERESFORD SA, OMENN GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049-1057, 1995
39. MALLAMACI F, ZOCCALI C, TRIPEPI G, et al: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61:609-614, 2002
40. WRONE EM, HORNBERGER JM, ZEHNDER JL, et al: Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15:420-426, 2004
41. LONDON GM, PANNIER B, AGHARAZII M, et al: Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 65:700-704, 2004
42. THAMBYRAJAH J, LANDRAY MJ, MCGLYNN FJ, et al: Abnormalities of endothelial function in patients with predialysis renal failure. Heart 83:205-209, 2000
43. TROYANOV S, HEBERT MJ, MASSE M, et al: Soluble Fas: A novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 41:1043-1051, 2003
44. PANNIER B, GUERIN AP, MARCHAIS SJ, et al: Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int 57:1091-1099, 2000
45. BLOCK GA, KLASSEN PS, LAZARUS JM, et al: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
46. KESTENBAUM B, SAMPSON JN, RUDSER KD, et al: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520-528, 2005